Introduction {#s1}
============

Timosaponin AIII (Timo AIII, IUPAC name: (2*S*,3*R*,4*S*,5*S*,6*R*)-2-\[(2*R*,3*R*,4*S*,5*R*,6*R*)-4,5-dihydroxy-6-(hydroxymethyl)-2-\[(1*R*,2*S*,4*S*,5\'*S*,6*R*,7*S*,8*R*,9*S*,12*S*,13*S*,16*S*,18*R*)-5\',7,9,13-tetramethylspiro\[5-oxapentacyclo\[10.8.0.0^2,9^.0^4,8^.0^13,18^\]icosane-6,2\'-oxane\]-16-yl\]oxyoxan-3-yl\]oxy-6-(hydroxymethyl)oxane-3,4,5-triol, CAS no: 41059-79-4) is a natural steroidal saponin with multiple-pharmacological activities, and it is primary isolated from Chinese Materia Medica *Anemarrhena asphodeloides* Bunge (well-known as Zhimu in Chinese) ([**Figure 1**](#f1){ref-type="fig"}) which has been used for treatment various diseases including arthralgia, hematochezia, cough, hemoptysis, and so on, in traditional Chinese medicine ([@B88]). Phytochemistry studies have identified more than 100 compounds from *A. asphodeloides* Bunge, and the main constitutes are steroidal saponins, flavonoids, phenylpropanoids, alkaloids, steroids, organic acids, anthraquinones, and so on ([@B88]). The total saponins, which are rich in rhizome, could be extracted by hot water under reflux and purified by EtOAc, n-BuOH, and H~2~O, and the content of saponins is more than 6% ([@B88]; [@B94]; [@B62]). Timo AIII, Timosaponin BII (Timo BII) and sarsasapogenin are three main active saponins isolated from *A. asphodeloides* Bunge ([**Figure 1**](#f1){ref-type="fig"}), and they have been identified as quality control and pharmacokinetic markers of diverse *A. asphodeloides* Bunge-contained Chinese herb formulas, such as TongGuanWan, Rhizoma Anemarrhenae-Phellodendron herb pair, guizhi-shaoyao-zhimu herb pair, zhimu-baihe herb pair, and so on ([@B78]; [@B88]; [@B79]; [@B95]). The biotransformation of Timo AIII from Timo BII could been mediated by β-D-glycosidase ([@B55]). Lu et al. also developed an enzyme associated five-step preparation method to produce high yield and purity Timo AIII from *A. asphodeloides* Bunge, which allowed us obtain efficient amount of Timo AIII for further study and product development ([@B55]). Although Timo AIII and Timo BII are mainly metabolized to sarsasapogenin *in vivo*, the sugar chain plays important roles in their pharmacological activities ([@B77]; [@B47]; [@B86]). The sugar chain in Timo AIII is indispensable to its pharmacological activities, and conversion of Timo BII to Timo AIII enhanced its cytotoxicity ([@B42]). So, Timo AIII presented most potential anti-cancer activity due to its specific sugar chain binding site. However, the hydrophobicity and low bioavailability of Timo AIII limited its efficacy *in vivo*, and many studies also focused on derivatization or drug delivery system design based on Timo AIII ([@B86]; [@B26]; [@B37]; [@B56]).

![*Anemarrhena asphodeloides* Bunge and the chemical structures of its main steroidal saponin ingredients. **(A)** *A. asphodeloides* Bunge. **(B)** Timosaponin AIII, Pubchem CID: 71306914, MF: C~39~H~64~O~13~. **(C)** Timosaponin BII, Pubchem CID: 44575945, MF: C~45~H~76~O~19~. **(D)** Sarsasapogenin, Pubchem CID: 92095, MF: C~27~H~44~O~3~.](fphar-11-00764-g001){#f1}

Timo AIII affected different numerous cellular signaling pathways and presented efficacy in different cell types and various disease models both *in vitro* and *in vivo*, such as cancer, Alzheimer\'s disease, depression, diabetic mellitus, colitis, and so on. Timo AIII dramatically inhibited the cancer cell growth at micromole level of concentration and selectively reduced the cancer cell viability but not normal cell ([@B42]). Thus, Timo AIII was proposed as a potent anti-cancer agent, and its anti-cancer activity and underlying mechanisms were most investigated in the previous studies ([@B21]). In this review, we comprehensively summarized the pharmacological activity, pharmacokinetics, and toxicity of Timo AIII according to the literatures in the recent decades. And this review provides an overview of the previous research related to Timo AIII, which is benefit for its further study and drug development.

Pharmacological Activities of Timo AIII {#s2}
=======================================

Cancer {#s2_1}
------

### Cytotoxicity {#s2_1_1}

Timo AIII and Timo BII are two well-known steroidal saponins in *Anemarrhena asphodeloides* Bunge while Timo BII presented less cytotoxic effect than Timo AIII in cancer cells ([@B42]). Induction of tumor cell death by cytotoxicity agent is the important mechanism of current cancer chemotherapy ([@B87]). Selectively kill cancer cell, regardless of normal cell, is the basic principle in cytotoxic anti-cancer drug development. Timo AIII could cause cell death in cancer cell but not in normal cell in the certain concentration ([@B42]; [@B87]; [@B102]). In addition, previous studies indicated that Timo AIII presented cytotoxicity effects in various kinds of cancer cells including breast cancer, hepatocellular cancer, cervical cancer, colon cancer, nasopharyngeal cancer, pancreatic cancer, lung cancer, renal cancer, chronic myelogenous leukemia, ovarian carcinoma, osteosarcoma, leukemia, melanoma, and so on. The detection methods and corresponding concentrations which presented cytotoxicity effect and/or IC50 in cancer and normal cell lines were summarized in [**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}. And the anti-cancer effects and underlying mechanisms of Timo AIII were most studied in breast cancer and hepatocellular cancer. However, only a small part of studies employed a positive control when evaluating the cytotoxicity of Timo AIII in their studies ([**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}). These results also indicated that the cytotoxic effect of Timo AIII to both cancer and normal cells were not all the same in the different contexts. In addition, the dosage of Timo AIII examined in animal models including mice, rat, and zebrafish were listed in [**Table 3**](#T3){ref-type="table"}.

###### 

The cytotoxicity effects of Timo AIII in different cancer cell lines.

  Cell line         Species   Category                              Detection method       Tested concentration or IC50                            Positive control         Reference
  ----------------- --------- ------------------------------------- ---------------------- ------------------------------------------------------- ------------------------ -----------
  **BT474**         Human     Breast cancer                         Annexin-PI staining    1\~10 µM (24 h) and IC50 \< 2.5µM(24 h)                 None                     ([@B33])
  **MDA-MB-231**    Human     Breast cancer                         Annexin-PI staining    1\~10 µM (24 h)                                         None                     ([@B33])
                                                                    CCK-8 assay            6--20 µM (24 h)                                         None                     ([@B61])
                                                                    MTT assay              0.001--1 µM (48 h)                                      None                     ([@B82])
                                                                    MTT assay              2--4 µM and IC50, 2 µM (48 h)                           None                     ([@B17])
  **MCF10A**        Human     Breast cancer                         Annexin-PI staining    1--10 µM (24 h)                                         None                     ([@B42])
  **MCF-7**         Human     Breast cancer                         MTT assay              1--100 µM and IC50=\~ 10 µM (48 h)                      None                     ([@B77])
                                                                    MTT assay              2--4 µM and IC50 = 2 µM (48 h)                          None                     ([@B17])
  **HepG2**         Human     Hepatocellular cancer                 MTT assay              1--100 µM and IC50=\~ 10 µM (48 h)                      None                     ([@B77])
                                                                    MTT assay              3.125--50 µM (24 and 48 h)                              None                     ([@B87])
                                                                    CCK-8 assay            6--20 µM (6, 24, and 48 h) and IC50 = 15.41 µM (24 h)   None                     ([@B61])
  **Hep3B**         Human     Hepatocellular cancer                 MTT assay              3.125\~50 µM (24 and 48 h)                              None                     ([@B87])
  **PLC/PRF/5**     Human     Hepatocellular cancer                 MTT assay              3.125\~50 µM (24 and 48 h)                              None                     ([@B87])
  **MHCC97L**       Human     Hepatocellular cancer                 MTT assay              3.125\~50 µM (24 and 48 h)                              None                     ([@B87])
  **HeLa**          Human     Cervical cancer                       MTT assay              1--100 µM and IC50=\~ 10 µM (48 h)                      Sarsasapogenin (50 µM)   ([@B77])
  **SUNE-1**        Human     Nasopharyngeal cancer                 MTT assay              1--100 µM and IC50=\~ 10 µM (48 h)                      None                     ([@B77])
  **HCT-15**        Human     Colon cancer                          SRB protein staining   2.5--20 µM and IC50 = 6.1 µM (3 days)                   None                     ([@B33])
  **HCT-116**       Human     Colon cancer                          SRB protein staining   IC50 = 5.5 µM (3 days)                                  None                     ([@B33])
  **HT-29**         Human     Colon cancer                          SRB protein staining   IC50 = 10.1 µM (3 days)                                 None                     ([@B33])
  **SW-480**        Human     Colon cancer                          SRB protein staining   IC50 = 13.1 µM (3 days)                                 None                     ([@B33])
  **SW-620**        Human     Colon cancer                          SRB protein staining   IC50 = 11.1 µM (3 days)                                 None                     ([@B33])
  **A549**          Human     Lung cancer                           CCK-8 assay            3--30 µM (24 h) and IC50 = \~10 µM                      None                     ([@B32])
                                                                    CCK-8 assay            6--20 µM (24 h)                                         None                     ([@B61])
  **A549/T**        Human     Lung cancer                           MTT assay              1.56--100 µM and IC50 = 5.12 µM (24 h)                  None                     ([@B75])
  **A375-S2**       Human     Melanoma                              MTT assay              1--8 µM (24 h)                                          None                     ([@B89])
  **B16-F10**       Murine    Melanoma                              MTS assay              10--100 nM (24 h)                                       None                     ([@B38])
  **WM-115**        Human     Melanoma                              MTS assay              10--100 nM (24 h)                                       None                     ([@B38])
  **PANC-1**        Human     Pancreatic cancer                     Modified MTT assay\*   5--20 µM (24 and 48 h)                                  Gemcitabine (1 mM)       ([@B58])
  **BxPC-3**        Human     Pancreatic cancer                     Modified MTT assay\*   5--20 µM (24 and 48 h)                                  Gemcitabine (1 mM)       ([@B58])
  **AsPC-1**        Human     Pancreatic cancer                     MTT assay              0--100 µM and IC50 = 22.1 µM (24 h)                     Gemcitabine (5 µM)       ([@B40])
  **786-O**         Human     Renal cancer                          MTT assay              2--8 µM (24 h)                                          None                     ([@B6])
  **A-498**         Human     Renal cancer                          MTT assay              2--8 µM (24 h)                                          None                     ([@B6])
  **ACHN**          Human     Renal cancer                          MTT assay              2--8 µM (24 h)                                          None                     ([@B6])
  **K562**          Human     Chronic myelogenous leukemia          CCK-8 assay            0.2--1.6 mg/L and IC50 = 1.01 mg/L (24h)                Adriamycin (4-32µg/m)    ([@B5])
  **K562/ADM**      Human     Chronic myelogenous leukemia          CCK-8 assay            16--128 mg/L and IC50 = 32.18 mg/L (24h)                Adriamycin (4-32µg/m)    ([@B5])
  **A2780/T**       Human     Ovarian carcinoma                     MTT assay              1.56--100 µM and IC50 = 4.64 µM (24 h)                  None                     ([@B75])
  **MG63**          Human     Osteosarcoma                          CCK-8 assay            3--15 µM (24 h) and IC50 = 12 µM                        None                     ([@B31])
  **U2OS**          Human     Osteosarcoma                          CCK-8 assay            3--15 µM (24 h)                                         None                     ([@B31])
  **Jurkat cell**   Human     T−cell acute lymphoblastic leukemia   CCK-8 assay            2--32 µM (24, 48, and 72 h)                             None                     ([@B90])

SRB, sulforhodamine-B; \*CellTiter 96 non-radioactive cell proliferation assay (MTT, Promega).

###### 

The cytotoxicity effects of Timo AIII in various normal cells.

  Cell line                Species   Category                             Detection method       Tested concentration or IC50          Positive control                   Reference
  ------------------------ --------- ------------------------------------ ---------------------- ------------------------------------- ---------------------------------- -----------
  **MRS-5**                Human     Normal lung epithelial               SRB protein staining   IC50 \> 50 µM (3 days)                None                               ([@B33])
  **Hs68**                 Human     Normal lung fibroblast               SRB protein staining   IC50 \> 50 µM (3 days)                None                               ([@B33])
  **L-02**                 Human     Normal hepatocyte                    MTT assay              8--512 µM and IC50 \> 128 µM (24 h)   None                               ([@B87])
  **Chang**                Human     Normal hepatocyte                    CCK-8 assay            6--20 µM (24 h)                       None                               ([@B61])
  **hPBMC**                Human     Peripheral blood mononuclear cells   MTT assay              2.5--40 µM (24 h)                     5-FU and paclitaxel (2.5--40 µM)   ([@B89])
  **HUVEC**                Human     Umbilical vein endothelial cell      MTT assay              0.5--8 µM (24 h)                      None                               ([@B102])
  **SK-N-SH**              Human     Neuroblastoma                        Western blot assay     2.5--10 µM (1 h)                      Tacrine (5 µM)                     ([@B46])
  **HEK**                  Human     Epidermal keratinocyte               MTT assay              1--200 nM (24 h)                      None                               ([@B39])
  **HDF**                  Human     Dermal fibroblast                    Cell migration assay   5--20 nM (12 h)                       None                               ([@B39])
  **Primary macrophage**   Mice      Peritoneal macrophage                Trypan blue method     2--5 µM (20 h)                        None                               ([@B49])
  **BV-2**                 Mice      Neuronal microglia                   Western blot assay     2.5--10 µM (1 h)                      Tacrine (5 µM)                     ([@B46])
  **RBL-2H3**              Rat       Cancerous basophil cells             ELISA assay            20 and 50 µM (4 h)                    Dexamethasone (10 µM)              ([@B47])

SRB, sulforhodamine-B.

###### 

The dose range of Timo AIII examined in animal models.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Animal                    Species     Administration approach                     Experimental duration   Tested dosage           Reference
  ------------------------- ----------- ------------------------------------------- ----------------------- ----------------------- -----------
  **Tübingen (TU)**\        Zebrafish   Immersed in drug-contained culture medium   24 h                    0.5, 1, and 2 µM        ([@B102])
  **(1 dpf)**                                                                                                                       

  **Tg(Fli-1: EGFP)y1**\    Zebrafish   Immersed in drug-contained culture medium   12 h                    0.5, 1, 2, and 3 µM     ([@B102])
  **(1 dpf)**                                                                                                                       

  **Nude mice**\            Mice        Intraperitoneal injection\                  3 weeks                 7.5 mg/kg               ([@B87])
  **(female)**                          (3 times per week)                                                                          

  **BALB/c nude mice**\     Mice        Intraperitoneal injection\                  30 days                 2 and 5 mg/kg           ([@B33])
  **(male, 5 weeks old)**               (3 times per week)                                                                          

  **C57BL / 6**             Mice        Intraperitoneal injection                   14 days                 12.5 and 25 mg/kg       ([@B38])

  **BALB/c nude mice**\     Mice        Intraperitoneal injection\                  10 days                 2.5 and 5 mg/kg         ([@B75])
  **(male)**                            (every two days)                                                                            

  **ICR**\                  Mice        Oral administration or\                     1 h                     5, 20, and 50 mg/kg     ([@B47])
  **(male)**                            intraperitoneal injection                                                                   

  **BALB/c nude mice**\     Mice        Oral administration\                        5 days                  10, 20, and 40 mg/kg    ([@B9])
  **(male, 7 weeks old)**               (twice daily)                                                                               

  **Wistar**\               Rat         Oral administration\                        5 days                  10, 20, and 40 mg/kg    ([@B9])
  **(male, 8 weeks old)**               (twice daily)                                                                               

  **BALB/c nude mice**\     Mice        Intraperitoneal injected\                   30 days                 7.5 mg/kg               ([@B56])
  **(5--6 weeks old)**                  (3 times per week)                                                                          

  **ICR**\                  Mice        Oral administration\                        7 days                  30, 90, and 270 mg/kg   ([@B20])
  **(6-8 weeks old)**                   (once daily)                                                                                

  **KK-Ay**                 Mice        Oral administration\                        8 weeks                 30, 90, and 270 mg/kg   ([@B20])
                                        (once daily)                                                                                

  **SD**\                   Rat         Oral administration                         14 days                 100 mg/kg               ([@B92])
  **(male)**                                                                                                                        

  **BALB/c nude mice**\     Mice        Intraperitoneally injected\                 10 days                 2.5 and 5 mg/kg         ([@B75])
  **(male)**                            (every two days)                                                                            

  **ICR**\                  Mice        Oral administration                         1 and 5 h               10, 20, or 40 mg/kg     ([@B46])
  **(male)**                                                                                                                        

  **SD**\                   Rat         Oral administration\                        7 days                  50--200 μg/kg           ([@B72])
  **(6 weeks old)**                     (once a day)                                                                                

  **ddY**\                  Mice        Intravenously Injected                      4-5 weeks               10 mg/kg                ([@B41])
  **(male,4 weeks old)**                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------

dpf, day post fertilization; ICR, Institute of Cancer Research.

### Promotion of Cell Apoptosis and Cell Cycle Arrest {#s2_1_2}

Induction of cell apoptosis and cell cycle arrest, which stops cancer cell proliferation and causes cell death, is the current main strategy in cancer treatment. The anti-cancer effect of Timo AIII was firstly reported ten years ago in 2008 by Sy et al. They identified that prolong treatment Timo AIII increased cytochrome c release and caspase activation in HeLa cells, and this pro-apoptosis effect of Timo AIII was mediated by over production of ROS and mitochondrial dysfunction ([@B77]). However, the anti-cancer effects of Timo AIII were most studied in breast cancer and hepatocellular cancer in the past decades. King et al. found that Timo AIII promoted breast cancer cell BT474, MDAMB231 and MCF10A apoptosis in a concentration-dependent manner, and the underlying mechanisms was co-related with target of rapamycin complex 1 (TORC1) inhibition and endoplasmic reticulum (ER) stress stimulated-apoptosis as well as the inhibition of major cell proliferation signaling transduction pathways ([@B42]). In the research field of hepatocellular cancer, Wang et al. found that Timo AIII enhanced the apoptosis cell population by activation of poly-ADP ribose polymerase (PARP) and caspase 3, and Z-VAD-FMK which is a cellular apoptosis inhibitor suppressed Timo AIII-induced cytotoxicity in human hepatocellular cancer cell lines including HepG2, MHCC97L, PLC/PRF/5 and Hep3B ([@B87]). And Timo AIII induced tumor cell apoptosis and increased cleavage PARP and caspase 3 expression in xenografted tumor mice model ([@B87]). In addition, Wang et al. proved that Timo AIIII reduced the expression of X-linked inhibitor of apoptosis protein (XIAP), which is one of the inhibitor of apoptosis proteins (IAP), in both hepatocellular cancer cells *in vitro* and *in vivo*, and suppression of XIAP by siRNA reduced the toxic sensitivity of Timo AIII in hepatocellular cancer cells ([@B87]). These results indicated that Timo AIII reduced the tumor growth by modulation of XIAP-mediated cellular caspase active apoptosis in hepatocellular cancer. Moreover, Kyoung et al. found that the anti-cancer effect of Timo AIII was most effective in HepG 2 liver cancer cell among MDA-MB-231 breast cancer cell, A549 no-small-cell lung cancer cell and Hep3B liver cancer cell ([@B61]). Timo AIII induced more than 90% cell apoptosis on the concentration of 15 µM, and the IC 50 (24h) was 15.41 µM in HepG2 cell. And Timo AIII-promoted cell apoptosis was associated with the decreased expression of Bcl-2, Mcl-1 and IAP family, and the increased release of cytochrome c and activities of caspase family including caspase 3, 7, 8, and 9 ([@B61]).

In addition, Timo AIII also presented efficacy in colon cancer, pancreatic cancer, lung cancer, osteosarcoma, melanoma, and leukemia. In colon cancer, human colon cancer HCT-15 cells treated various concentrations of Timo AIII for 12 or 24 h appeared different degree of G~0~/G~1~ and G~2~/M phase cell cycle arrest, and the cell cycle regulation effect of Timo AIII was associated with the down-regulation of cyclin A, cyclin B1, CDK2, CDK4, pRb, proliferating cell nuclear antigen (PCNA) and c-Myc ([@B33]). Moreover, Timo AIII promoted cell apoptosis by induction of DNA fragmentation, activation of caspases, induction of cleaved-PARP and reduction of Bcl-xL and Bcl-2 expression in HCT-15 cells *in vitro*. In line with this results, Timo AIII significantly decreased the tumor volume in HCT-15 cell-bearing athymic nude mice *in vivo* ([@B33]). In melanoma, Timo AIII arrested the cell cycle at G~0~/G~1~ phase and enhanced the cell apoptosis by up-regulation of cleavage-caspase 3 expression in human melanoma A375-S2 cells ([@B89]). And Timo AIII enhanced the expression of iNOS which resulted in the elevated release of NO, and Timo AIII-induced cleavage of caspase 3 was attenuated by iNOS inhibitors DTT and 1400W in A375-S2 cells. Timo AIII increased the expression of JNK and ERK, and their inhibitors enhanced Timo AIII-induced cell death but decreased cleavage-caspase 3 expression in A375-S2 cells ([@B89]). Thus, JNK and ERK seem play protective roles in the Timo AIII-induced cell death. In pancreatic cancer, Kim et al. demonstrated that Timo AIII increased the number of apoptotic cells which accompanied with the reduction of mRNA expression of anti-apoptosis proteins survivin, Bcl-2 and Bcl-xl, and Timo AIII elevated cell cycle distribution at sub-G1 phase which might result from the down-regulation of cell cycle regulators cyclin-D and upregulation of cyclin-dependent inhibitor p21 in human pancreatic cancer cell AsPC-1 ([@B40]). And combination commercial available anti-cancer drug dasatinib, which is a Src inhibitor, with Timo AIII enhanced the pro-apoptosis effect by regulation of PARP and caspase 3 expressions in AsPC-1 cells ([@B40]). Interestingly, Timo AIII enhanced the ERK/Src phosphorylation at low concentration while decreased both the amount of phosphorylated and total protein at high concentration ([@B40]), which revealed that high concentration of Timo AIII mainly resulted in cell death. Timo AIII also inhibited the tumor growth by activation of caspase-3 which stimulated cellular apoptosis on pancreatic cancer PANC-1 cell-xenograft nude mice model ([@B66]). In osteosarcoma and lung cancer, Timo AIII significantly induced cell apoptosis by regulation of caspase 3, caspase 7 and PARP expressions in MG63 human osteosarcoma cells ([@B31]), and induced cell apoptosis and cell cycle arrest at G~0~/G~1~ phase in human no-small-cell lung cancer cell A549 ([@B32]). Timo AIII also concentration-dependently induced cell apoptosis by upregulation of Bax and down regulation of Bcl-2 in T−cell acute lymphoblastic leukemia Jurkat cells ([@B90]).

Thus, we could conclude that the anti-cancer efficacy of Timo AIII was well studied, especially hepatocellular cancer and breast cancer, and the mainly underlying mechanism was induction of cell apoptosis ([**Figure 2**](#f2){ref-type="fig"}) and cell cycle arrest ([**Figure 3**](#f3){ref-type="fig"}). In addition, the XIAP might be potential pharmacological target of Timo AIII.

![Schematic overview of the underlying mechanisms related to the induction of apoptosis, ROS production, and mitochondrial dysfunction by Timo AIII.](fphar-11-00764-g002){#f2}

![Schematic overview of the underlying mechanisms related to the cell cycle arrest effect of Timo AIII.](fphar-11-00764-g003){#f3}

### Induction of ER Stress, ROS Generation, and Mitochondrial Dysfunction {#s2_1_3}

Normal endoplasmic reticulum (ER) function is essential for maintaining the cellular homeostasis, and ER stress presents in cancer cells due to its nutrient limitative and hypoxic tumor micro-environment ([@B10]). However, chronic ER stress stimulated activation of cellular apoptosis pathways which could result in cancer cell death, and the anti-cancer effects of various natural products were resulted from the induction of intracellular ER stress ([@B36]). King et al. found that Timo AIII time-dependently enhanced the ER stress by up-regulating the protein levels of PDI, calreticulin, GRP78, ATF4, and TRIB3 and the phosphorylation levels of eIF2α and PERK, which are ER stress markers ([@B42]). And Timo AIII also enhanced the genes expression in cholesterol biosynthesis pathways in breast cancer cell BT474, MDAMB231 and MCF10A. However, the total cholesterol levels were not changed and the cholesterol biosynthesis regulator SREBP-2 was significantly activated in Timo AIII treated cell ([@B42]). Thus, the cell death induced by Timo AIII was not due to the biosynthesis of cholesterol, and the regulation of cholesterol biosynthesis by Timo AIII supported its ER stress induction activity ([**Figure 4**](#f4){ref-type="fig"}).

![Schematic overview of the underlying mechanisms related to the induction of ER stress by Timo AIII.](fphar-11-00764-g004){#f4}

Mitochondria regulates many cellular physical functions including energy metabolism, reactive oxidant species (ROS) generation and apoptosis, and Chiu et al. claimed that mitochondria played a central role in cancer development and suggested that mitochondria-targeted therapeutic approach was valuable in cancer ([@B7]). Kyoung et al. found that Timo AIII dramatically induced apoptosis in HepG2 cells, which might be co-related to the translocation of Smac/Diablo and HtrA2/Omi from cytosol to mitochondria consequently triggered cell apoptosis ([@B61]). ROS could be either cause or result of mitochondria dysfunction which promotes disruption of intracellular homeostasis and cancer cell death ([@B44]; [@B67]; [@B101]). Timo AIII induced intracellular ROS accumulation which could be cleared by anti-oxidant NAC and might be an important cause of cell death in triple negative breast cancer cell MDA-MB-231 ([@B82]). Consistently, Timo AIII concentration-dependently increased the intracellular ROS and anti-oxidant enzymes including SOD and catalase in HeLa cells, which indicated that Timo AIII impaired intracellular redox homeostasis ([@B77]). In addition, Timo AIII destroyed mitochondrial membrane potential, mitochondrial permeability transition, and release of cytochrome c, and the mitochondria was the main sources of ROS-induced by Timo AIII in HeLa cells ([@B77]). So, targeting ROS production and mitochondria dysfunction might be essential mechanisms for Timo AIII-caused cancer cell death ([**Figure 2**](#f2){ref-type="fig"}).

### Anti-Angiogenesis {#s2_1_4}

Tumor angiogenesis, which is triggered by tumor-secreted angiogenic factors, transports nutrient to tumor and promotes tumor growth and metastasis. Targeting tumor angiogenesis and vascular normalization have been a promising anti-cancer drug development strategy, and several agents have been developed ([@B85]; [@B27]). The anti-tumor effect of Timo AIII on pancreatic cancer cell PANC-1 bearing nude mice model was co-related to the down-regulation of mRNA and protein levels of the angiogenic factor VEGF ([@B66]). Timo AIII inhibited the mRNA expression of VEGF-1, and suppressed the EGF-triggered Src/STAT3/ERK signaling pathway activation in a concentration-dependent manner in pancreatic cancer cell AsPC-1 ([@B40]). Zebrafish and vascular endothelial cell have been considered as the well-known *in vivo* and *in vitro* models for anti-angiogenesis activity evaluation with the advantages of low cost, time saving, and easy observation ([@B63]; [@B12]). Zhou et al. found that Timo AIII presented anti-angiogenesis effect in zebrafish *in vivo* and human umbilical vein endothelial cells (HUVECs) *in vitro* ([@B102]). Timo AIII inhibited the intersegmental vessels (ISVs) and sub-intestinal vessels (SIVs) growth in transgenic zebrafish line Tg(Fli-1: EGFP)^y1^ which expressed enhanced green fluorescence protein (EGFP) in vascular endothelial cells. Timo AIII also inhibited the endothelial cell proliferation, migration, invasion, and tube formation in HUVECs. And the underlying mechanism might be closely related to the down-regulation of VEGFRs and suppression of VEGF/PI3K/Akt/MAPK signaling pathway. So, the anti-tumor angiogenesis effect of Timo AIII also contributes to its anti-cancer capability, and VEGFR might be potential pharmacological target of Timo AIII ([**Figure 5**](#f5){ref-type="fig"}).

![Schematic overview of the signaling pathways related to the anti-angiogenesis activity of Timo AIII.](fphar-11-00764-g005){#f5}

### Anti-Metastasis {#s2_1_5}

Most of the cancer patients die from cancer metastasis which consists of multiple physical processes and have long been associated with cancer cell migration and invasion ([@B19]). Matrix metalloproteinase (MMP) is the vital pharmacological target in cancer progression, which degrades extracellular matrix, affects the cancer microenvironment, and initiates cancer metastasis ([@B70]; [@B57]). Various signaling pathways, including MAPKs, src/FAK, beta-catenin, NF-κB, STAT3, and so on are involved in the regulation of MMPs expressions ([@B65]; [@B59]). Timo AIII significantly inhibited the proteolytic activity and mRNA expression of MMP-2/9 which are key regulators in cell migration and invasion in human no-small-cell lung cancer cells A549 and H1299, and the underlying mechanisms might be related to the suppression of ERK1/2, Src/FAK, and beta-catenin signaling pathways ([@B32]). Consistently, Timo AIII significantly decreased MMP-2/9 expression, and inhibited cell migration and invasion in human osteosarcoma cells MG63 and U2OS. The underlying mechanism was involved in suppression of Src/FAK/MAPKs signaling pathway and down-regulation of transcription factors CREB and b-catenin ([@B31]). In addition, Timo AIII decreased mRNA expression of MMP-9 in human pancreatic cancer cell AsPC-1 ([@B40]) and suppressed HGF-induced MMP-9 expression in triple negative breast cancer cell MDA-MB-231 ([@B82]).

MicroRNAs (miRNAs), which are small-noncoding RNA molecules and regulate the target genes expression, are classified as oncomiRs (tumor inducers) and tumor suppressor miRNA. And miRNA were well recognized for cancer treatment and diagnose in recent decades ([@B35]; [@B68]; [@B11]). The expression level of cancer stem cell phenotype regulator B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1), which is also a component of the polycomb repressive complex 1 (PRC1) and its transcription is dramatically regulated by Myc, is up-regulated in various cancers especially breast cancers ([@B13]; [@B23]). Dimiri et al. suggested that the oncogenic activity of BMI1 was also mediated by miR-200c/141 cluster-BMI1 auto-regulatory loop in cancer cells ([@B14]). Timo AIII concentration-dependently induced tumor cell senescence and inhibited cell oncogenic phenotypes, including migration, invasion, and colonies formation in soft-agar in both triple negative cancer cell MDA-MB-231 and non-triple negative cancer cell MCF-7 ([@B17]). Gergely et al. proved that the inhibitory effect of Timo AIII on cell oncogenic phenotype was mediated by the up-regulation of miR-200c/141 cluster and down-regulation of BMI1, mono-ubiquitination of histone H2A at lysine 119 (H2AUb) and Myc in both MDA-MB-231 and MCF-7 cells ([@B17]). There are also accumulated evidences which revealed the tumor suppressive role of miR-129-5p in various cancers ([@B53]; [@B69]; [@B71]). Timo AIII inhibited cell migration and invasion among the concentration range of 2 to 6 µM in which Timo AIII not affected the cell viability and cell cycle distribution in human renal cancer cells 786-O and A-498 ([@B6]). And this non-toxic inhibitory effect of Timo AIII on cell migration and invasion was co-related with the down-regulation of cysteine protease cathepsin c expression, which was regulated by PI3K/Akt/miR-129-5p signaling axis ([@B6]).

The inflammatory infiltration state of cancer microenvironment plays crucial role in cancer growth, metastasis, and resistance, which is mainly regulated by COX2/PGE2/EP and NF-κB signaling cascades ([@B25]; [@B81]). The inhibition of these processes presented potential therapeutic effect in various cancers ([@B98]; [@B52]). Timo AIII suppressed the migration capability of murine melanoma cell B16-F10 and human melanoma cell WM-115, which were induced or not induced by COX-2 stimulator 12-O-tetradecanoylphorbal-13-acetate (TPA), and it was closely associated with its concentration-dependent inhibitory effect on endogenous COX-2 expression and PGE2 production ([@B38]). Timo AIII also reduced protein levels of NF-κB, IKKα, IκBα, and PGE2 receptors including EP2 and EP4 in B16-F10 cells ([@B38]). In line with these *in vitro* experiment results, Timo AIII significantly inhibited the metastasis of B16-F10 cells to lung with reduction of COX2 and NF-κB expression in mice *in vivo* ([@B38]). Many growth factors induce cancer cell proliferation, migration, and invasion, which contribute to cancer cell motility and intravasation ([@B19]). Hepatocyte growth factor (HGF), which promotes various cancer cell metastasis, triggered cancer cell migration and invasion *via* cMet-ERK-COX2 and MAPK signaling pathways ([@B73]; [@B43]). Timo AIII concentration-dependently inhibited HGF-induced cell migration and invasion which were blocked by COX2 inhibitor NS398 and ERK inhibitor PD98059 in triple negative breast cancer cell MDA-MB-231 ([@B82]). Timo AIII also significantly attenuated HGF-induced intracellular p-cMet and COX2 expressions as well as nuclear ERK phosphorylation and ATF2 expression in MDA-MBA-231 cells ([@B82]).

Thus, Timo AIII inhibited cancer stem cell phenotype, including cell migration and invasion, and subsequently suppressed cancer metastasis by targeting MMPs, BMI1, and cancer inflammatory infiltration ([**Figure 6**](#f6){ref-type="fig"}).

![Schematic overview of the signaling pathways related to the anti-metastasis and anti-multi drug resistance (MDR) activity of Timo AIII.](fphar-11-00764-g006){#f6}

### Anti-Resistance and Synergistic Anti-Cancer Effect {#s2_1_6}

Multiple drug resistance (MDR) is a severe problem in current cancer therapy ([@B18]; [@B84]). Elevating the sensitivity of therapeutic drug to resistant-cancer cell by combination with other agents might be a promising therapeutic strategy. Timo AIII concentration-dependently caused cytotoxicity, cell cycle arrest, and caspase-dependent apoptosis in PANC-1 and BxPC-3 cells, which were resistance to gemcitabine in different degree, and enhanced the sensitivity to gemcitabine in these pancreatic cancer cells ([@B58]). The underlying mechanism of Timo AIII enhanced the sensitivity of gemcitabine on cell cycle dysfunction, and apoptosis was involved in activation of pro-apoptotic proteins in PI3K/Akt signaling cascade ([@B58]). Timo AIII also inhibited PI3K/Akt signaling pathway on adriamycin (ADM)-resistant human chronic myelogenous leukemia cell K562 ([@B5]). And the anti-tumor effects of Timo AIII on taxol-resistance lung and ovarian cancers were co-related to the suppression of PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways ([@B75]). In addition, Ginsenosides including compound K, Rb1, and Rc enhanced the cytotoxicity of Timo AIII in MG63 human osteosarcoma cells, in which Rb1 and Rc increased the population of apoptosis cell caused by Timo AIII ([@B31]). Thesis results indicate that Timo AIII could enhance the cancer cell apoptosis and suppressed the cell survival signaling, and ginsenoside might present synergistic effect on Timo AIII-induced cancer cell death and metastasis.

The metabolism and transport of intracellular drug to extra cell contributes to MDR, which is also called drug efflux. The ATP-binding cassette (ABC) transporter family including multi-drug resistance protein 1 (MDR1; also known as P-glycoprotein and ABCB1), MDR-associated protein 1 (MRP1; also known as ABCC1) and breast cancer resistance protein (BCRP; also known as ABCG2) regulates the process of drug efflux, which also overexpresses in many drug-resistant cancer cells ([@B24]). Timo AIII increased intracellular adriamycin (ADM) concentration and presented reversal effect on ADM-resistant human chronic myelogenous leukemia cell K562 in a concentration-dependent manner, and the underlying mechanisms were related to the down-regulation of P-glycoprotein (P-gp) and MRP1 ([@B5]). Moreover, Timo AIII attenuated the expression of P-gp and enhanced cell apoptosis in taxol-resistance human lung cancer cell A549/T and human ovarian cancer A2780/T *in vitro* and A549/T cell injected nude mice *in vivo* ([@B75]). Thus, the inhibition of drug efflux by down-regulation of drug transporters expression was a key mechanism account for the anti-resistant capability of Timo AIII in cancer cells ([**Figure 6**](#f6){ref-type="fig"}).

### Negative Regulated Cell Death by Autophagy {#s2_1_7}

Autophagy characterized by the formulation of autophagic vacuoles which degrade and recycle the dysfunctional proteins and damaged organelles subsequently maintains the intracellular homeostasis ([@B2]). Autophagy is a double-edged sword in cancer development, progression, and treatment, which could be tumor-suppressive, tumor-promoting, or neutral under different conditions ([@B1]). PI3K/Akt/mTOR signaling pathway plays a key role in regulation of autophagy ([@B8]). Timo AIII notably induced cellular autophagic morphology *via* inhibition of PI3K/Akt/mTOR signaling pathway in Jurkat cells ([@B90]). Lok et al. found that Timo AIII suppressed the mTOR signaling and trigged autophagy while this process was not all the same with rapamycin-induced autophagy in HeLa cells ([@B54]). Timo AIII modulated specific transcriptional mechanisms and caused the up-regulation of cholesterol biosynthesis pathways for supporting the formation of autophagic vacuoles which capture ubiquitin proteins ([@B54]). Timo AIII-induced autophagy was co-related with elevated intracellular calcium concentration and accelerated the clearance of ubiquitin protein aggregation which induced by proteinase inhibitor MG132 ([@B54]). In addition, Timo AIII inhibited the mTORC1 and promoted selective protective autophagy in breast cancer cells ([@B42]). The inhibition of autophagy by chloroquine enhanced the cytotoxicity of Timo AIII in MDA-MB-231 and MCF 10A cells regardless of BT474 cell ([@B42]). In line with this result, Timo AIII increased the accumulation and conversion of cytosol LC3 I to autophagosome membrane located LC3 II, which revealed the autophagy induction effect in HeLa cells ([@B54]), and Timo AIII-induced apoptosis was potentiated in the presence of autophagy inhibitor 3-methyladenine (3-MA) or silenced beclin-1 gene which is a key regulator of autophagy ([@B42]). Moreover, Timo AIII induced autophagy in hepatocellular cancer cells both *in vitro* and *in vivo*, which mediated by AMPKα activation and mTOR inhibition ([@B87]). The inhibition of autophagy by Atg5 silence increased the cytotoxicity of Timo AIII in hepatocellular cancer cells, which revealed the cyto-protective role of autophagy in Timo AIII-induced hepatocellular cancer cell death ([@B87]). Timo AIII increased autophagy vacuoles, Beclin-1 and LC3 levels in human melanoma A375-S2 cells, and Timo AIII-induced apoptosis was accelerated by the autophagy inhibitor 3-MA ([@B89]). These results indicated that Timo AIII-induced autophagy might act as the role to promote tumor cell survival *in vitro*, and mTORC1 might be the potential target of Timo AIII ([**Figure 7**](#f7){ref-type="fig"}).

![Schematic overview of the underlying mechanisms and signaling pathways related to the cellular protective autophagy activity of Timo AIII.](fphar-11-00764-g007){#f7}

Neuronal Disorders {#s2_2}
------------------

### Alzheimer**\'**s Disease {#s2_2_1}

Alzheimer\'s disease (AD), which is a progressive neurodegeneration disease and characterized by disorder of memory and cognitive functions, is the most common type of dementia with poor therapeutic efficacy until now ([@B64]). Several pathology features, including neuro-inflammation, accumulation of β-amyloid plaques and tau protein, and deficient cholinergic transmission were found in the brain of AD patients ([@B83]). Acetylcholinesterase (AChE) degrades acetylcholine and lowers cholinergic activity and its selective inhibitor donepezil has been used for AD treatment in clinics ([@B3]). Lee et al. found that orally administration of Timo AIII (10, 20 and 40 mg/kg) significantly ameliorated the scopolamine-caused mice memory impairment in both passive avoidance test and Morris water maze test, and tacrine (10 mg/kg)-treated mice served as the positive control ([@B46]). Timo AIII elevated the acetylcholine level in scopolamine-treated mice brain which was correlated to its concentration dependently inhibition of the AChE activity (IC 50 = 35.4 µM). In addition, the elevation levels of pro-inflammatory cytokines including TNF-α, IL-6 and IL-1β have been found in the AD brain, and microglia triggered neuro-inflammation has been considered contribution to AD progression ([@B91]). Timo AIII decreased the expression of pro-inflammatory cytokines TNF-α and IL-1β in the brain of scopolamine-treated mice, and the underlying mechanism was associated with the suppression of NF-κB signaling pathway activation in both microglia and neuron ([@B46]). Though the anti-AD activity of Timo AIII was demonstrated *in vivo*, whether Timo AIII could cross blood-brain barrier need to be further studied. Thus, we could conclude that Timo AIII was potentially for AD therapy due to its inhibition on AChE activity and NF-κB-mediated neuro-inflammation ([**Figure 8**](#f8){ref-type="fig"}).

![Overview of the underlying mechanisms of the Alzheimer\'s disease protective effect of Timo AIII.](fphar-11-00764-g008){#f8}

### Depression {#s2_2_2}

Depression is a serious psychiatric disease and dramatically disrupted the quality of life ([@B74]). Although these are multiple pharmacological and physical strategies for depression treatment in clinic, various side effects accompany with the positive outcomes ([@B80]). Timosaponin B-III (Timo B-III) which is also one of the main natural steroidal saponins in *A. asphodeloides* Bunge prevented from depression in a mouse postpartum depression model ([@B99]). Timo AIII (30 mg/kg) also presented anti-depression activity according to the experiment results from open field test, tail suspension test and forced swimming test in mice, and fluoxetine-treated mice served as the positive control. However, the anti-depression effect of Timo B-III was more effective than Timo AIII ([@B28]). Thus, further studies about the anti-depression effect of Timo B-III are more valuable than Timo AIII.

Diabetic Mellitus {#s2_3}
-----------------

*Anemarrhena asphodeloides* Bunge is an important constitute of herb medicine formulas, like TongGuanWan, Bai-Hu-Jia-Rensheng-Tang, Rhizoma Anemarrhenae-Phellodendron herb pair and guizhi-shaoyao--*A. asphodeloides* herb pair, which have been applied for treatment of diabetic mellitus for thousands of years in China ([@B41]; [@B72]; [@B78]; [@B20]; [@B100]). But the active constitutes of *A. asphodeloides* Bunge for diabetic mellitus treatment was not fully elucidated. The diabetic mellitus protective effect of Timo AIII was firstly investigated on streptozocin (STZ)-induced diabetic and normal mice in 1996 ([@B41]). In diabetic mice model, Timo AIII (1 and 10 mg/kg) significantly promoted the salivary flow. And combination of CaCl~2~ (2 and 4 mg/kg) with Timo AIII (0.1 mg/kg) enhanced the pilocarpine-induced saliva secretion when compared with Timo AIII alone ([@B41]). However, Nian et al. found that the glucosidase inhibitory effect of flavones, including mangiferin and isomangiferin, were more effective than steroidal saponins including Timo AIII and Timo BII, which revealed the more potent anti-diabetic mellitus effects of flavones than saponins isolated from *A. asphodeloides* Bunge ([@B62]). And Yuan et al. found Timo BII prevent from diabetic nephropathy by suppression the inflammation in alloxan-induced mice ([@B97]). These results revealed that the anti-diabetic mechanisms were different between steroidal saponins and flavones ingredients of *A. asphodeloides* Bunge and the anti-diabetic mellitus activity of Timo AIII might be due to its anti-inflammatory property.

Others {#s2_4}
------

### Anti-Platelet and Anti-Thrombotic Activity {#s2_4_1}

Platelet activation and aggregation have been considered as the main pathology of many cardiovascular diseases, such as coronary heart disease, atherosclerosis, and strokes ([@B96]). The inhibition of thromboxane prostaglandin (TP) receptor which blocked thromboxane (Tx) A2 pathway has been suggested as the efficient drug target for inhibition of platelet activation and aggregation ([@B16]; [@B34]). Timo AIII inhibited U46619-induced platelet aggregation by reduction of ADP secretion *in vitro* and prevented thrombus formation in mice *in vivo* ([@B9]). The thromboxane (Tx) A2 receptor activity and Gq signaling pathway were suppressed by Timo AIII, and the anti-platelet aggregation activity was enhanced by combination Timo AIII with current known antiplatelet agents including PGE1 and SQ29548. So, Timo AIII might be potential for development of cardiovascular drugs for its anti-platelet and anti-thrombotic activity targeting thromboxane (Tx) A2 receptor.

### Anti-UVB Radiation {#s2_4_2}

UVB radiation was harmful to skins which resulted in cellular damage, mutation, inflammation, photoaging, and consequently, photocarcinogenesis progression ([@B45]). Natural herbs were precious library for discovery of UV protective agents ([@B48]; [@B60]). Kim et al. found that Timo AIII, which isolated from Chinese herb *A. asphodeloides* Bunge, protected against UVB-induced cell migration and invasion in both human epidermal keratinocytes (HEKs) and dermal fibroblasts (HDF), and the underlying mechanism were involved in the inhibition of Akt/MAPK signaling pathway and down-regulation of MMP9 ([@B39]). Timo AIII reduced UVB-induced up-regulation of COX2 and inflammatory cytokines including TNF-α and IL-6 expressions, which was associated with the down-regulation of pro-inflammatory factor NF-κB. In addition, Timo AIII reduced UVB-induced DNA damage and deposition of 8-oxo-7, 8-dihydro-2\'-deoxyguanosine (8-oxo-dG), which were mediated by down regulation of cell cycle arrest--related genes PCNA and SMC1. Thus, the UBV-radiation protective effect of Timo AIII might be mainly due to its anti-inflammatory, anti-cell migration, and anti-cell invasion capabilities.

### Anti-Colitis {#s2_4_3}

Timo AIII concentration-dependently inhibited in LPS- or peptidoglycan-stimulated upregulation of COX2, iNOS, and pro-inflammatory cytokines TNF-α and IL-6 expressions in mice peritoneal macrophages, which accompanied with suppression of MAPKs and NF-κB signaling pathways activation ([@B49]). Moreover, Lim et al. found that Timo AIII reduced the amount of LPS binding to TLR and restored the balance of Th17/Treg cells in mice peritoneal macrophages, and these *in vitro* experiment results were in line with the anti-inflammatory effects of Timo AIII on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice *in vivo* ([**Figure 9**](#f9){ref-type="fig"}).

![Overview of the underlying mechanisms of the anti-inflammation and immune regulation effects of Timo AIII.](fphar-11-00764-g009){#f9}

### Anti-Allergy {#s2_4_4}

Timo AIII inhibited the passive cutaneous anaphylaxis (PCA) reaction and scratching behaviors in mice while further studies revealed that sarsasapogenin, one of the metabolites of Timo AIII, was the active metabolic compound in Timo AIII-induced anti-allergy ([@B47]). Lim et al. also found that Timo AIII inhibited the differentiation of T cell to Treg cell *in vitro* ([@B49]). Thus, Timo AIII might also be able to regulate the immune system ([**Figure 9**](#f9){ref-type="fig"}).

### Anti-Virus {#s2_4_5}

Respiratory syncytial virus (RSV) has been identified as the most important cause of lower respiratory tract infections and results in some mortality in young children and elderly ([@B29]; [@B4]). Although several inhibitors targeting RSV has been found over decades, there is still no antiviral drugs or vaccines approved for the prevention or treatment of RSV infections ([@B22]). Joung et al. isolated the Timo AIII from the BuOH fraction of *A. asphodeloides* Bunge and found that Timo AIII significantly inhibited the propagation of RSV in HEp-2 cells (IC50 = 1.0 µM) ([@B30]). Furthermore, ribavirin--treated group served as the positive control with the IC50 value of 1.15 µM, which was higher than Timo AIII. Thus, we could conclude that Timo AIII presented potential anti-virus activity while its action mechanisms still needs further studies.

Pharmacokinetics and Toxicity {#s3}
=============================

Pharmacokinetics and toxicity studies play vital roles in the process of drug development. Several analytical methods were developed for detection of the saponins including Timo AIII and Timo BII in animal blood plasma after administration of single compound or herb formulas ([@B50]; [@B76]; [@B15]). Timo AIII is one of the important active ingredients of Baihe Zhimu decoction which was used for depression treatment in traditional Chinese medicine for a long history in China ([@B95]). Yang et al. found that Timo AIII presented in the blood after oral administration of Baihe Zhimu decoction by an AB Sciex QTRAP ((R)) 5500 mass spectrometer in both normal and depression rats ([@B95]). Lee et al. detected the blood concentration of Timo AIII using LC-MS in mice, and they found that its maximum blood concentration was 104.7 ± 20.7 ng/µL after oral administration of Timo AIII (50 mg/kg) for 4 to 6 h ([@B46]). And this result was consistent with efficacy results that the memory-enhancing effect of Timo AIII after orally administration for 5 h was more effective than 1 h. However, Liu et al. found that the Cmax, Tmax, t1/2, and MRT (mean residence time) of Timo AIII were 18.2 ± 3.1 ng/mL, 2.3 ± 0.57 h, 4.9 ± 2.0 h, and 7.1 ± 1.4 h respectively after oral administration of Timo AIII (6.8 mg/kg) in health male SD rat ([@B51]). Moreover, Timo AIII presented slow eliminated rate in the liver and caused hepatotoxicity which might result from its induction of intracellular ROS and down-regulation of bile acid transporters capabilities ([@B92]; [@B93]). And mangiferin, which is an active component in *A. asphodeloides* Bunge and presented anti-oxidant ability, attenuated Timo AIII-induced hepatotoxicity. The absorption, distribution, metabolism, and elimination (ADME) processes and toxicity of Timo AIII still need further study in both health and disease models including mice, rat, and human.

Discussion {#s4}
==========

Timo AIII presented various pharmacological activities including anti-cancer, anti-AD, anti- diabetic mellitus, anti-colitis, anti-coagulant, and so on, while these researches were mainly conducted *in vitro*. The most effective activity of Timo AIII is anti-cancer, especially breast cancer and hepatocellular cancer, and the underlying mechanism are co-related with its anti-metastasis, anti-resistance, cytotoxicity, pro-apoptosis, and induction of cell cycle arrest, ROS, ER stress, and mitochondria dysfunction. Previous studies revealed that Timo AIII-induced autophagy might act as the role to promote tumor cell survival *in vitro*. These lack the *in vivo* evidence that explore whether inhibition of autophagy could elevate the anti-cancer effect of Timo AIII. And the autophagy induction effect of Timo AIII might contribute to other diseases, like AD and PD, in which activation of autophagy accelerates clearance of misfolding proteins. We also identified VEGFR, XIAP, BMI1, thromboxane (Tx) A2 receptor, mTOR, NF-κB, COX-2, MMPs, AChE, and so on are as the vital pharmacological targets of Timo AIII. Moreover, the anti-inflammatory effect of Timo AIII is also wealth for further studies, which accounts for its anti-AD, anti-metastasis, ant-metastasis, anti-UVB radiation, and anti-colitis activities. The toxicity, especially hepatotoxicity, and pharmacokinetics including ADME of Timo AIII are worth to investigate in diverse animal models. In conclusion, Timo AIII is potent as a compound or leading compound for further drug development while still needs in-depth studies.
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